ClearPoint Neuro (CLPT) Competitors

ClearPoint Neuro (NASDAQ:CLPT) and Pro-Dex (NASDAQ:PDEX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, community ranking, media sentiment, valuation, profitability and analyst recommendations.

Which has better valuation & earnings, CLPT or PDEX?

Pro-Dex has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ClearPoint Neuro	$23.95M	6.43	-$22.09M	-$0.84	-6.69
Pro-Dex	$46.09M	1.45	$7.07M	$0.58	33.59

Does the media prefer CLPT or PDEX?

In the previous week, ClearPoint Neuro and ClearPoint Neuro both had 2 articles in the media. ClearPoint Neuro's average media sentiment score of 1.19 beat Pro-Dex's score of 0.31 indicating that ClearPoint Neuro is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ClearPoint Neuro	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pro-Dex	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do insiders & institutionals believe in CLPT or PDEX?

30.1% of ClearPoint Neuro shares are owned by institutional investors. Comparatively, 15.3% of Pro-Dex shares are owned by institutional investors. 6.1% of ClearPoint Neuro shares are owned by company insiders. Comparatively, 42.6% of Pro-Dex shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Does the MarketBeat Community favor CLPT or PDEX?

Pro-Dex received 128 more outperform votes than ClearPoint Neuro when rated by MarketBeat users. However, 86.96% of users gave ClearPoint Neuro an outperform vote while only 60.91% of users gave Pro-Dex an outperform vote.

Company	Underperform	Outperform
ClearPoint Neuro	Outperform Votes 20 86.96%	Underperform Votes 3 13.04%
Pro-Dex	Outperform Votes 148 60.91%	Underperform Votes 95 39.09%

Is CLPT or PDEX more profitable?

Pro-Dex has a net margin of 4.13% compared to ClearPoint Neuro's net margin of -78.84%. Pro-Dex's return on equity of 6.50% beat ClearPoint Neuro's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ClearPoint Neuro	-78.84%	-76.92%	-43.94%
Pro-Dex	4.13%	6.50%	4.01%

Do analysts recommend CLPT or PDEX?

ClearPoint Neuro currently has a consensus target price of $12.00, suggesting a potential upside of 113.52%. Given ClearPoint Neuro's higher probable upside, equities research analysts plainly believe ClearPoint Neuro is more favorable than Pro-Dex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ClearPoint Neuro	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Pro-Dex	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Which has more volatility and risk, CLPT or PDEX?

ClearPoint Neuro has a beta of 1.05, suggesting that its stock price is 5% more volatile than the S&P 500. Comparatively, Pro-Dex has a beta of 0.41, suggesting that its stock price is 59% less volatile than the S&P 500.

Summary

Pro-Dex beats ClearPoint Neuro on 9 of the 16 factors compared between the two stocks.